October 2023
Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting
EUGENE, Ore., Oct. 24, 2023 (GLOBE NEWSWIRE) — Cascade Prodrug Inc. (Cascade), a private preclinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting hypoxia, today announced a poster presentation highlighting preclinical data for it’s lead candidate CPD100Li at the SITC 2023 Annual Meeting, being held November 3-5 in San Diego, CA.
Poster details are as follows:
Title: Modulating the tumor microenvironment via hypoxia activated prodrug CPD100Li induced cell death synergistically enhances anti-CTLA-4 immunotherapy
Poster / Abstract Number: 1086
Date / Time: November 4, 2023 / 9:00 a.m. – 8:30 p.m. PT
Location: Exhibit Hall Exhibit Halls A and B1 – San Diego Convention Center
Full text of the abstract will be available on the SITC website on Oct. 31 at 9am ET, and the poster will be made available on the Company’s website www.cascadeprodrug.com after November 6th.
About Cascade Prodrug, Inc.
Cascade Prodrug is an oncology focused biotechnology company employing a unique platform technology targeting hypoxia, a common feature of the tumor microenvironment, to develop small molecule prodrugs that are inactive at oxygen normal tissue levels but convert to its cytotoxic form around the hypoxic regions of tumors, selectively killing cancer and immunosuppressive cells. Our lead candidate CPD100Li has shown robust in-vivo activity in multiple tumor types including lung, colon and pancreatic cancer as a stand-alone agent or in combination with chemotherapeutics and checkpoint inhibitors.
CPD100Li is currently entering IND-enabling studies and will initially target pancreatic cancer as well as combinations with check point inhibitors. In 2022, Cascade was granted Orphan Drug Designation by the FDA for the treatment of pancreatic cancer for CDP100Li. For more information on Cascade and CPD100Li please visit www.cascadeprodrug.com.
FORWARD-LOOKING STATEMENTS:
The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Cascade, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.
Contact:
Cascade Prodrug Inc.
Allan Cochrane
President & Co-Founder
allan@cascadeprodrug.com
Eric Malek
Chief Business Officer
eric@cascadeprodrug.com
October 2022
Letter to Investors and Friends
Dear Investors and Friends of Cascade Prodrug Inc,
On behalf of our leadership team, I am pleased to inform you that the FDA has granted the company Orphan Drug Designation [ODD] for CPD 100Li for the treatment of pancreatic cancer.
At a high level this designation provides:
- Tax credits up to 50% for research and clinical drug testing expenses
- Eligibility for market exclusivity for 7 years AFTER pre-market approval
- Waiver of new drug application [NDA] application fee [Approximately worth $2M+]
- Pediatric Research Equity Act Exemption
In summary, this designation on the part of the FDA clearly supports the direction and focus the company is pursuing under its preclinical development and commercial partnering initiatives.
We thank our investors and friends for their support.
Kind Regards,
Al
Allan Cochrane,
Co-Founder and Managing Director
Cascade Prodrug, Inc.
May 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer
PORTLAND, Ore. – Research by Oregon State University has uncovered a potential new therapy for pancreatic cancer, whose survival rate is among the lowest of all malignancies.
About one person in 64 will be diagnosed with pancreatic cancer, according to the American Cancer Society. The pancreas is an abdominal organ that regulates blood sugar and also helps with digestion.
Pancreatic ductal adenocarcinoma, usually abbreviated to PDAC, is responsible for more than 90% of pancreatic cancer cases, said Adam Alani of the OSU College of Pharmacy, who led the preclinical study. Just 11% of PDAC patients live for at least five years after their diagnosis, he said…
Apr. 4, 2017
New Drug Delivery System Could Help Fight Tumors
April 4 (UPI) — Researchers at Oregon State University have developed a new cancer-drug delivery system that may help overcome the challenge of treating solid tumors often resistant to treatment.
Carcinomas, a type of cancer that affect the lung, prostate, colon and breast, are solid tumors that contain hypoxic or low oxygen regions that cause slow growth and resistance to drug treatment to shrink or kill the tumor.
The team at Oregon State found a way to use a prodrug, a pharmacologically inactive compound that is metabolized by the body into an active drug, to overcome the hypoxia of carcinoma tumors…
Apr. 3, 2017
New Drug Delivery System Shows Promise For Fighting Solid Tumors
PORTLAND, Ore. – A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.
Carcinomas that affect the breast, lung, prostate and colon are among the solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue.
These solid masses often contain hypoxic regions, where the concentration of oxygen in the tissue is low. Hypoxic cancer cells grow slowly, and that makes them less susceptible to the drugs prescribed to kill or damage them…